The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps. Thursday, May 29, 2025 Drug News.

GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps. Newswire.ca - Mon May 26, 8:10AM CDT.

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and ...

Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric ...

In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by approximately 50% compared ...

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in ...

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $76.59 billion and impressive gross profit margins of 71.81%, announced that the US Food and Drug ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.